{"nctId":"NCT05529992","briefTitle":"A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease","startDateStruct":{"date":"2023-01-03","type":"ACTUAL"},"conditions":["Gaucher Disease"],"count":20,"armGroups":[{"label":"Velaglucerase Alfa (VPRIV)","type":"EXPERIMENTAL","interventionNames":["Drug: Velaglucerase Alfa"]}],"interventions":[{"name":"Velaglucerase Alfa","otherNames":["VPRIV"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion:\n\n* Has a documented, confirmed diagnosis of type 1 Gaucher disease based on the following, as determined by the investigator:\n\n  1. Decreased glucocerebrosidase (GCB) activity level that is ≤30% of normal or\n  2. Decreased GCB activity level that is \\>30% of normal, but with confirmation of genetic mutation test\n* Is at least 2 years of age, inclusive, at screening\n* Is naive to treatment for Gaucher disease (Has not received treatment for Gaucher disease \\[investigational or approved products\\] within the 12 months prior to screening) OR Is receiving or has recently received Imiglucerase ERT (Has received Imiglucerase treatment within the 12 months prior to screening and not within the 14 days prior to screening)\n* Has Gaucher disease-related hematological abnormalities, defined as\n\n  1. Hemoglobin levels of ≥1 g/dL below the lower limit of normal for their age and gender AND/OR\n  2. A platelet count of \\<90 × 10\\^9/L below the lower limit of normal for their age and gender\n* Has Gaucher disease-related viscera abnormalities, defined as the following:\n\n  * Participant has at least moderate splenomegaly, assessed by palpation (2 to 3 cm below the left costal margin), or by abdominal radiology scan (magnetic resonance imaging \\[MRI\\] or computed tomography \\[CT\\] scan, with spleen volume \\>5 times normal) AND/OR\n  * Participant has hepatomegaly, assessed by palpation or by abdominal radiology scan (MRI or CT scan); Participants who have undergone splenectomy must have satisfied these criteria for this study.\n\nExclusion:\n\n* Has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease as assessed by the investigator\n* Has had a splenectomy or an active, clinically significant spleen infarction within the 12 months prior to screening\n* Has received treatment with any investigational drug or device within 30 days prior to screening, or within 5 half-lives of that investigational product, whichever is greater; such treatment during the study will not be permitted\n* Is currently receiving red blood cell growth factor (eg, erythropoietin), chronic systemic corticosteroids, or has been on such treatment within the 6 months prior to screening\n* Presents with non-Gaucher disease related exacerbated anemia at screening\n* Has experienced a severe (grade 3 or higher) infusion-related hypersensitivity reaction (anaphylactic or anaphylactoid reaction) to any ERT (approved or investigational)","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE)","description":"Adverse event(AE)=any untoward medical occurrence in clinical investigation participant administered a drug;it does not necessarily have to have causal relationship with this treatment. AE can therefore be any unfavorable\\&unintended sign (example,clinically significant abnormal laboratory value),symptom/disease temporally associated with use of drug whether or not it is considered related to drug. TEAE=any event emerging or manifesting at or after initiation of investigational product or any existing event that worsens in either intensity or frequency following exposure to investigational product. SAE=any untoward clinical manifestation of signs, symptoms, or outcomes(whether considered related to investigational product or not)\\&at any dose: results in death,is life-threatening,requires in-patient hospitalization/prolongation of hospitalization,results in persistent/significant disability/incapacity,results in congenital abnormality/birth defect,or is an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With TEAEs","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as any event emerging or manifesting at or after the initiation of the investigational product or any existing event that worsens in either intensity or frequency following exposure to the investigational product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Infusion-related Reactions Reported as an Adverse Event","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. An infusion-related AE was defined as an AE that 1) began either during or within 12 hours after the start of the infusion and 2) was judged as possibly or probably related to the study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Development of Anti-VPRIV Antibodies and Neutralizing Antibodies at Week 53","description":"Percentages were rounded off to the nearest single decimal place.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Changes in Laboratory Assessments at Week 53","description":"Clinical laboratory assessments included hematology and serum chemistry. Any clinically significant changes in the clinical laboratory assessment values based on the investigator's interpretation were reported. Only categories with at least one participant with event are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Changes in Laboratory Assessments at Week 53: Urinalysis","description":"Any abnormal changes in the urinalysis assessment values based on the investigator's interpretation were reported. Urinalysis comprised of the following parameters: bilirubin, ketones, glucose, nitrite, occult blood, protein, and urobilinogen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With at Least One Abnormal Change in an Infusion Vital Sign Parameter at Week 53","description":"Participants with atleast 1 abnormal change (above or below normal) in an infusion vital sign parameter of pulse, temperature, respiratory rate,\\& blood pressure were reported. Normal ranges for each vital sign parameter were, pulse (beats per minutes \\[bpm\\]): 40-100(≥12 years old), 55-95(≥6 but \\<12 years old), 65-110(≥2 but \\<6 years old); body temperature(degree Celsius\\[˚C\\]): 36.5 to 37.2(all age groups),respiration rate(breaths/minutes):12-24(≥12 years old),12-22 (≥6 but \\<12 years old),20-30(≥2 but \\<6 years old);systolic blood pressure(BP) \\[millimeters of mercury{mm Hg}\\]: high: ≥140 (≥18 years old), ≥20+ 80+ 2\\*age(\\<18 years old), low: \\<90 (≥18 years old), \\< -20+ 80+ 2\\*age(\\<18 years old); diastolic BP(mm Hg):high:≥90 (≥18 years old), ≥20+ (80+2\\*age)\\*(2/3) (\\<18 years old) low: \\<50 (≥18 years old), \\< -20+ (80+2\\*age)\\*(2/3) (\\<18 years old). As per planned analysis,data was collected in a combined manner for all participants irrespective of age. Only non-zero categories are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Measurements at Week 53","description":"Participants with clinically significant changes in any ECG measurement, such as PR, QRS, QT, corrected QT intervals, and heart rate based on the investigator's interpretation were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 53 in Hemoglobin Concentration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"1.305"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 53 in Platelet Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":"27.68"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 53 in Normalized Liver Volume","description":"Normalized liver volume was measured by abdominal magnetic resonance imaging (MRI) or computed tomography (CT) scan. Liver volume was normalized for percent body weight.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"0.917"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 53 in Normalized Spleen Volume","description":"Spleen volume was normalized for percent body weight.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","spread":"1.627"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 53 in 36-item Short Form General Health Survey (SF-36) Scores","description":"SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100 for each component summary (i.e., PCS and MCS), where higher scores are associated with less disability and better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.015","spread":"5.8464"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.858","spread":"12.5103"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 53 in Childhood Health Questionnaire-Parent Form 50 (CHQ-PF50) Scores","description":"The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains (global health, physical functioning, role/social limitations (emotional/behavioral and physical), bodily pain/discomfort, behavior, global behavior, mental health, self-esteem, general health perceptions, change in health, parental impact (emotional and time), family activities, and family cohesion) which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A positive change from Baseline indicates improved well-being.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"12.745"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"11.462"}]}]}]},{"type":"SECONDARY","title":"Cmax: Maximum Observed Serum Concentration for VPRIV at Week 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5220","spread":"1610"}]}]}]},{"type":"SECONDARY","title":"Serum Concentration for VPRIV at Week 37","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3450","spread":"1390"}]}]}]},{"type":"SECONDARY","title":"Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for VPRIV","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.00","spread":null}]}]}]},{"type":"SECONDARY","title":"AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for VPRIV","description":"ng\\*min/mL denotes nanograms\\*minutes per milliliter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"235000","spread":"85000"}]}]}]},{"type":"SECONDARY","title":"Terminal Phase Elimination Half-life (T1/2) for VPRIV","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.12","spread":"2.81"}]}]}]},{"type":"SECONDARY","title":"Oral Clearance (CL) for VPRIV","description":"mL/min/kg denotes milliliters per minutes per kilogram.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.27","spread":"2.87"}]}]}]},{"type":"SECONDARY","title":"Apparent Steady-state Volume of Distribution (Vss) for VPRIV","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":"52.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 53 in Biomarker: Plasma Chemokine [C-C Motif] Ligand 18","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-58.94","spread":"14.339"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 53 in Biomarker: Glucopsychosine","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.88","spread":"14.359"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":20},"commonTop":["Upper respiratory tract infection","Cough","Pyrexia","Conjunctivitis","Fall"]}}}